Novartis shutters MorphoSys sites, lays off staff
BioPharma Dive - 19 Dec 2024Novartis shutters MorphoSys sites, lays off staff ...
morphosys
Novartis shutters MorphoSys sites, lays off staff ...
MorphoSys Presents Latest Data from the Phase 2 MANIFEST Study Evaluating the Potential of Pelabresib in the Treatment of Myelofibrosis
ACCESS Newswire - 25 Jun 2025MorphoSys Presents Latest Data from the Phase 2 MANIFEST Study Evaluating the Potential of Pelabresib in the Treatment of Myelofibrosis ...
Bill Meury brings new perspective to Incyte as Hoppenot retires; Ex-MorphoSys CEO leads revitalized Vor Bio
Endpoints News - 27 Jun 2025Bill Meury brings new perspective to Incyte as Hoppenot retires; Ex-MorphoSys CEO leads revitalized Vor Bio ...
Endgültiges Aus für Morphosys
Laborjournal - 09 Jan 2025Endgültiges Aus für Morphosys ...
Novartis' $2.9B MorphoSys bet stumbles as safety signal delays filing by years
Fierce Biotech - 29 Oct 2024Novartis' $2.9B MorphoSys bet stumbles as safety signal delays filing by years ...
Pelabresib delay prompts Novartis to close MorphoSys units, 330 jobs hit
FirstWord Pharma - 19 Dec 2024Pelabresib delay prompts Novartis to close MorphoSys units, 330 jobs hit ...
Novartis says 330 jobs hit as it closes MorphoSys sites
Reuters - 19 Dec 2024Novartis says 330 jobs hit as it closes MorphoSys sites ...
Novartis to shutter 2 MorphoSys sites, lay off 330 staffers in post-buyout consolidation
Fierce Pharma - 19 Dec 2024Novartis to shutter 2 MorphoSys sites, lay off 330 staffers in post-buyout consolidation ...
Swiss pharma giant Novartis to close biotech firm Morphosys
SWI swissinfo.ch - 19 Dec 2024Swiss pharma giant Novartis to close biotech firm Morphosys ...
Novartis sheds MorphoSys staff, sites after pelabresib delay
Pharmaphorum - 19 Dec 2024Novartis sheds MorphoSys staff, sites after pelabresib delay ...
Morphosys’ antibody still shining – for J&J
European Biotechnology Magazine - 07 Apr 2025Morphosys’ antibody still shining – for J&J ...
Merger Squeeze-Out of MorphoSys Minority Shareholders Approved at 2024 Annual General Meeting
ACCESS Newswire - 25 Jan 2025Merger Squeeze-Out of MorphoSys Minority Shareholders Approved at 2024 Annual General Meeting ...
Novartis takes $800M MorphoSys writedown mere months after closing acquisition
Endpoints News - 29 Oct 2024Novartis takes $800M MorphoSys writedown mere months after closing acquisition ...
Novartis gains global rights to Galapagos, MorphoSys' experimental atopic dermatitis drug MOR106
FirstWord Pharma - 17 Apr 2025Novartis gains global rights to Galapagos, MorphoSys' experimental atopic dermatitis drug MOR106 ...
Novartis: launch of Morphosys drug by could be 2027 or later
Reuters - 21 Nov 2024Novartis: launch of Morphosys drug by could be 2027 or later ...
MorphoSys Announces U.S. Antitrust Clearance of Proposed Acquisition by Novartis Under HSR Act
ACCESS Newswire - 26 Apr 2025MorphoSys Announces U.S. Antitrust Clearance of Proposed Acquisition by Novartis Under HSR Act ...
Novartis highlights overall M&A track record following MorphoSys impairment
Endpoints News - 29 Oct 2024Novartis highlights overall M&A track record following MorphoSys impairment ...
MorphoSys Announces That Its Patents Were Ruled Invalid in Patent Lawsuit Against Janssen and Genmab
ACCESS Newswire - 27 Jan 2025MorphoSys Announces That Its Patents Were Ruled Invalid in Patent Lawsuit Against Janssen and Genmab ...
MorphoSys Appoints Jean-Paul Kress, M.D., as New Chief Executive Officer
ACCESS Newswire - 26 Apr 2025MorphoSys Appoints Jean-Paul Kress, M.D., as New Chief Executive Officer ...